TRADING ON THE OTC - SYMBOL : PGUZ
OUR PRODUCTS : MEDICAL BACKGROUND & RESEARCH DATA : MANAGEMENT : INVESTORS/NEWS : LINKS : CONTACT US

 

 

 

 

 

Home Page  |  

 

June 27, 2006
PRESS RELEASE 

PEGASUS/HEARTVIEW DELIVERS FIRST SHIPMENT OF 55 HEARTVUE 6S SYSTEM ELECTROCARDIOGRAPH UNITS TO CHINA

Palm Beach Gardens , FL , Market Wire, June 27 th , 2006. Pegasus/HeartView, LLC (Symbol: PGUZ-OTC) today announced that they have completed an initial shipment of 55 HeartView 6S System units to China . The original sale to Pegasus PharmGroup, a private B.C.,Canada-based company, encompasses a total sale of 10,000 units over a ten year period for a cumulative value of $ 50,000,000 USD. (See the original Press Release dated February 9 th , 2006, “Pegasus/HeartView Sign Multi-Year Sales Agreement……”)

PharmGroup and its marketing subsidiary, Pegasus Lifecare Inc., will focus their sales efforts of the breakthrough ECG technology units on the more than 20,000 major hospitals in China through its extensive distributor network throughout southern Asia . The first shipment of the HeartVue 6S System units were specially produced for the Asian markets, featuring a Chinese interface throughout the software operating functions.

HeartView, LLC is planning to exhibit the HeartView 6S System in the upcoming World Congress of Cardiology, September 2 nd – 6 th , 2006 in Barcelona , Spain , where over 25,000 delegates are expected to attend. This major conference is a joint meeting of the European Society of Cardiologists and the World Heart Federation (WHF), and will be a forum featuring the latest research in cardiology and heart disease prevention. HeartView will be part of the Emerging Technologies Showcase at the conference.

The HeartVue 6S System is an advanced electrocardiograph screening technology for early, non-invasive screening of heart disease. The technology uses only 4 limb wires (6 standard ECG leads) from the patient's wrists and ankles. The device includes proprietary software that converts the electric conductivity of the cardiac tissue into a three dimensional color-coded visual picture, which is simple for physicians to interpret. The ECV device allows testers to observe the condition of the heart muscle as well as the intensity of the heart stress load. The device immediately provides a visual of the patient's heart and an electrocardiogram, the mainstay in the screening of acute and chronic heart disease (CHD)

HeartView, LLC, Cleveland , Ohio holds the worldwide patent, manufacturing and marketing rights of the HeartVue 6S System. An earlier version of this electrocardiograph screening system has already been cleared for sale in Europe and there is a patent pending for the device in the United States .

or more information, please contact Paul Davey, Investor Services at (778) 389-0915
( Canada ). Email: paul@pegasusbiosciences.com, or Daniel P. Kesonen, Chairman & CEO of Pegasus Pharmaceuticals Inc., Palm Beach Florida at (561) 626-9901. Further

For investor information, contact Paul Davey at (778) 389-0915.

Safe Harbor :
This news release may include forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United states Securities and Exchange Act of 1934, as amended with respect to achieving corporate objectives, developing additional project interests, the Company's analysis of opportunities in the acquisition and development of various project interests and certain other matters. These statements are made under the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements herein.

 


 


Copyright © 2006, Pegasus Pharmaceuticals Inc.